Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
JAK2 inhibitors: JAK2 inhibitors and the innate immune response in mutant CALR-driven MPNs
Stoiber-Sakaguchi, D. (PI), Podar, K. (CoPI) & Kollmann, K. (CoPI)
Gesellschaft für Forschungsförderung NÖ (GFF)
01.01.2022 → 31.12.2026
Project: Funded Research
-
APOG: ACCESS POINT Oncology
Podar, K. (PI), Stoiber-Sakaguchi, D. (CoPI), Pecherstorfer, M. (CoPI), Georg, P. (CoPI), Kieseberg, P. (CoPI), Fossati, P. (CoPI), Lütgendorf-Caucig, C. (CoPI) & Slade, D. (CoPI)
01.01.2020 → 31.12.2026
Project: Funded Research
-
STAT3: STAT3 isoforms in hematopoietic disorders
Stoiber-Sakaguchi, D. (PI), Podar, K. (CoPI) & Casanova, E. (CoPI)
Gesellschaft für Forschungsförderung NÖ (GFF)
01.01.2021 → 31.12.2024
Project: Funded Research
-
PROTACs : Targeting Transcription factors for cancer therapy utilizing PROteolysis-TArgeting Chimera (PROTACs)
Podar, K. (PI)
01.08.2020 → 31.10.2022
Project: Forschungsimpulse › Research Time Out (RTO)
-
Biomarker: Biomarker- based therapeutic prevention of bone metastases in breast cancer. Defining the pathophysiologic impact of the endosteal niche
Vallet, S. (PI), Podar, K. (CoI) & Wiesner, C. (CoPI)
Gesellschaft für Forschungsförderung NÖ (GFF)
01.12.2019 → 31.12.2023
Project: Funded Research
Research output
-
PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism
Oudaert, I., van den Broecke, L., Aksoy, O., Lind, J., Vallet, S., Van der Vreken, A., Ates, G., Massie, A., Maes, K., De Veirman, K., De Bruyne, E., Vanderkerken, K., Podar, K. & Menu, E., Feb 2026, In: Molecular Oncology. 20, 2, p. 447-463 17 p.Research output: Journal article (peer-reviewed) › Journal article
Open Access -
Atovaquone and selinexor as a novel combination treatment option in acute myeloid leukemia
Weiss, S., Zdársky, B., Witalisz-Siepracka, A., Edtmayer, S., Holzer, A., Heindl, K., Casanova, E., Podar, K. & Stoiber, D., 31 Mar 2025, In: Cancer Letters. 613, p. 217501 217501.Research output: Journal article (peer-reviewed) › Journal article
Open Access1 Link opens in a new tab Citation (Scopus) -
Can we develop effective direct or indirect inhibitors of transcription factors? On the clinical evolution of protein degraders for multiple myeloma therapy
Meli, R., Aksoy, O., Vallet, S., Slade, D. & Podar, K., 2025, In: Expert Opinion on Therapeutic Targets. 29, 3, p. 101-115 15 p.Research output: Journal article (peer-reviewed) › Journal article
1 Link opens in a new tab Citation (Scopus) -
Cure for multiple myeloma?
Podar, K., May 2025, In: Memo - Magazine of European Medical Oncology. 18, 2, p. 108-115 8 p.Research output: Journal article (peer-reviewed) › Review article
Open Access1 Link opens in a new tab Citation (Scopus) -
DDX3X facilitates adaption to proteotoxic stress by regulating the translation of MAPKAPK2 and the stability of TMCO1 via stress granules in multiple myeloma
Fan, F., Jiang, S., Ni, E., Wang, Z., Wang, Y., Zuo, L., Ma, C., Vallet, S., Xu, A., Xu, J., Podar, K., Sun, C. & Hu, Y., 03 Nov 2025, In: Blood. 146, Supplement 1, p. 3944-3944Research output: Journal article (peer-reviewed) › Conference contribution to journal
Prizes
Activities
- 1 Organising an event (Science to science)
-
Lower Austrian Conference on Cancer Research (LACCR)
Podar, K. (Organiser) & Vallet, S. (Co-Organiser)
13 Nov 2025Activity: Participating in/organising an event › Organising an event (Science to science)